Modified Allergens for Immunotherapy
- 16 February 2018
- journal article
- review article
- Published by Springer Nature in Current Allergy and Asthma Reports
- Vol. 18 (2) , 9
Abstract
During the past few decades, modified allergens have been developed for use in allergen-specific immunotherapy (AIT) with the aim to improve efficacy and reduce adverse effects. This review aims to provide an overview of the different types of modified allergens, their mechanism of action and their potential for improving AIT.Keywords
Funding Information
- Swiss National Science Foundation (320030–159870)
This publication has 121 references indexed in Scilit:
- Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptidesClinical and Translational Allergy, 2013
- Specific IgE response to different grass pollen allergen components in children undergoing sublingual immunotherapyClinical and Molecular Allergy, 2012
- Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injectionsJournal of Allergy and Clinical Immunology, 2012
- Mechanisms of allergen‐specific immunotherapyClinical and Translational Allergy, 2012
- A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreSJournal of Allergy and Clinical Immunology, 2011
- Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimerMolecular Immunology, 2011
- Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppressionJournal of Experimental Medicine, 2009
- In vivo switch to IL-10–secreting T regulatory cells in high dose allergen exposureJournal of Experimental Medicine, 2008
- A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6Biological Chemistry, 2008
- Immunotherapy with Allergen PeptidesAllergy, Asthma & Clinical Immunology, 2007